Related Experiment Video
Updated: May 27, 2025
10:13
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
11.1K
Linking LEDGF/p75 Overexpression With Microsatellite Instability and KRAS Mutations: A Small-Scale Study in
Victoria Liedtke1, Thomas Wartmann2, Wenjie Shi2
1Faculty Environment and Natural Sciences, Brandenburg University of Technology Cottbus-Senftenberg, Senftenberg, Germany.
Cancer Control : Journal of the Moffitt Cancer Center
|February 18, 2025
Summary
Lens epithelium-derived growth factor splice variant of 75 kDa (LEDGF/p75) is upregulated in colorectal cancer (CRC) and correlates with KRAS and MSH2 mutations. This finding suggests LEDGF/p75 as a potential biomarker for early CRC detection and personalized therapy.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Colorectal cancer (CRC) is a leading cause of cancer-related deaths globally, with projected increases in incidence.
- Early detection and identification of novel biomarkers are crucial for improving patient outcomes.
- Lens epithelium-derived growth factor splice variant of 75 kDa (LEDGF/p75) is implicated as a stress-related oncogene.
Purpose of the Study:
- To investigate the expression levels of LEDGF/p75 and UBC13 in colorectal cancer tissues.
- To analyze the correlation between LEDGF/p75 expression and specific genetic mutations (KRAS, MSH2) in CRC patients.
- To evaluate the potential of LEDGF/p75 as a prognostic biomarker for colorectal cancer.
Main Methods:
- Western blot analysis was performed on 15 colorectal cancer (CRC) tissue samples and adjacent non-tumor tissues to assess protein expression.
- mRNA expression data from 521 patient samples from The Cancer Genome Atlas (TCGA) database were used for validation.
- Next-generation sequencing (NGS)-based mutation analysis was conducted on all patient samples prior to protein analysis.
Main Results:
- LEDGF/p75 expression was significantly elevated in 73.3% (11/15) of tumor tissues compared to adjacent tissues.
- UBC13, a key regulator in signaling molecule degradation, was also increased in 60.0% (9/15) of tumor tissues.
- A strong correlation was observed between LEDGF/p75 overexpression and KRAS (75%) and MSH2 (100%) mutations, with co-overexpression noted in 6/6 patients.
Conclusions:
- This study confirms the upregulation of LEDGF/p75 in colorectal cancer and its association with KRAS and MSH2 mutations.
- LEDGF/p75's interaction with DNA damage response proteins may contribute to drug resistance and tumor aggressiveness.
- LEDGF/p75 shows potential as an independent prognostic biomarker for personalized CRC therapy, warranting further investigation for therapeutic targeting.
More Related Videos
Related Concept Videos
02:38The Ras Gene
6.1K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.1K
01:24Small GTPases - Ras and Rho
3.9K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
3.9K
02:07Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K